PF
ALXN

Phoenix Financial’s Alexion Pharmaceuticals ALXN Stock Holding History

Phoenix Financial’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-162,858
Closed -$29.9M – 459
2021
Q2 		$29.9M Buy
162,858
+2,242
+1% +$385K 0.57% 65
2021
Q1 		$24.6M Sell
160,616
-24,087
-13% -$3.73M 0.56% 61
2020
Q4 		$28.8M Buy
+184,703
New +$23.7M 0.77% 52
2020
Q3 		– Sell
-254,703
Closed -$27.1M – 374
2020
Q2 		$27.1M Buy
254,703
+40,000
+19% +$4.25M 1.15% 23
2020
Q1 		$18.8M Buy
214,703
+40,000
+23% +$3.93M 0.95% 32
2019
Q4 		$18.8M Sell
174,703
-18,230
-9% -$1.95M 0.78% 57
2019
Q3 		$18M Buy
+192,933
New +$21.7M 0.85% 49

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Phoenix Financial's ALXN Position: Q3 2021 in Review

Phoenix Financial sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 162,858 shares — an estimated $29.9M sold.

Phoenix Financial first reported a position in ALXN in Q3 2019 and held it in 7 quarters. The position peaked at $29.9M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Phoenix Financial reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Phoenix Financial sold 162,858 Alexion Pharmaceuticals shares in Q3 2021, an estimated $29.9M.
  • Phoenix Financial first reported a position in Alexion Pharmaceuticals in Q3 2019 and held it in 7 quarters.
  • Phoenix Financial's Alexion Pharmaceuticals position peaked at $29.9M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Phoenix Financial's 13F filing for Q3 2021, filed 27 Oct 2021.